Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000134.xml
Diabetologie und Stoffwechsel 2021; 16(S 02): S290-S298
DOI: 10.1055/a-1515-8779
DOI: 10.1055/a-1515-8779
DDG-Praxisempfehlung
Adipositas und Diabetes
Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.
Änderung 1: ADA Consensus Report Nutrition Therapy for Adults with Diabetes or Prediabetes
Begründung: Ergänzung Ernährungsempfehlungen für Patienten mit Diabetes mellitus/Prädiabetes
Stützende Quellenangabe: [10]
Änderung 2: STEP-1 Studie
Begründung: Aktuelle Phase-3-Studienergebnisse
Stützende Quellenangabe: [20]
Änderung 3: SURPASS-1 Studie
Begründung: Aktuelle Phase-3-Studienergebnisse
Stützende Quellenangabe: [25]
Publication History
Article published online:
21 October 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Lindström J, Louheranta A, Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236 DOI: 10.2337/diacare.26.12.3230.
- 2 Knowler WC, Barrett-Connor E, Fowler SE. et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346: 393-403 DOI: 10.1056/NEJMoa012512.
- 3 Lean MEJ, Powrie JK, Anderson AS. et al. Obesity, Weight Loss and Prognosis in Type 2 Diabetes. Diabet Med 1990; 7: 228-233 DOI: 10.1111/j.1464-5491.1990.tb01375.x.
- 4 Williamson DF, Thompson TJ, Thun M. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504 DOI: 10.2337/diacare.23.10.1499.
- 5 Wing RR, Bahnson JL, Bray GA. et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575 DOI: 10.1001/archinternmed.2010.334.
- 6 Eeg-Olofsson K, Cederholm J, Nilsson PM. et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13,087 patients. Diabetologia 2009; 52: 65-73 DOI: 10.1007/s00125-008-1190-x.
- 7 Buse JB, Wexler DJ, Tsapas A. et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-493 DOI: 10.2337/dci19-0066.
- 8 Wang Z, Hoy WE. Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 2004; 58: 888-893 DOI: 10.1038/sj.ejcn.1601891.
- 9 Pischon T, Boeing H, Hoffmann K. et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120 DOI: 10.1056/NEJMoa0801891.
- 10 Evert AB, Dennison M, Gardner CD. et al. Nutrition therapy for adults with diabetes or prediabetes: A consensus report. Diabetes Care 2019; 42: 731-754 DOI: 10.2337/dci19-0014.
- 11 Reynolds AN, Akerman AP, Mann J. Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses. PLoS Med 2020; 17: e1003053 DOI: 10.1371/journal.pmed.1003053.
- 12 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapy of Type 2 Diabetes. Exp Clin Endocrinol Diabetes 2019; 127: S73-S92 DOI: 10.1055/a-1018-9106.
- 13 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551 DOI: 10.1016/S0140-6736(17)33102-1.
- 14 Gregg EW, Chen H, Wagenknecht LE. et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA – J Am Med Assoc 2012; 308: 2489-2496 DOI: 10.1001/jama.2012.67929.
- 15 Nationale VersorgungsLeitlinie (NVL) Typ-- Diabetes. 1. Auflage.
- 16 Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: A systematic review of the literature. Obes Rev 2006; 7: 183-200 DOI: 10.1111/j.1467-789X.2006.00250.x.
- 17 Piercy KL, Troiano RP, Ballard RM. et al. The Physical Activity Guidelines for Americans. JAMA 2018; 320: 2020 DOI: 10.1001/jama.2018.14854.
- 18 Vilsbøll T, Christensen M, Junker AE. et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344 DOI: 10.1136/bmj.d7771.
- 19 Pi-Sunyer X, Astrup A, Fujioka K. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22 DOI: 10.1056/nejmoa1411892.
- 20 Wilding JPH, Batterham RL, Calanna S. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384: 989-1002 DOI: 10.1056/nejmoa2032183.
- 21 Muscelli E, Mari A, Casolaro A. et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348 DOI: 10.2337/db07-1315.
- 22 Liu C, Li C, Cai X. et al. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. Bioorg Chem 2021; 106 DOI: 10.1016/j.bioorg.2020.104492.
- 23 Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34 DOI: 10.1016/S1262-3636(08)73397-4.
- 24 Alvarez E, Martínez MD, Roncero I. et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005; 92: 798-806 DOI: 10.1111/j.1471-4159.2004.02914.x.
- 25 Rosenstock J, Wysham C, Frías JP. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021; DOI: 10.1016/S0140-6736(21)01324-6.
- 26 Rubino F, Nathan DM, Eckel RH. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care 2016; 39: 861-877 DOI: 10.2337/dc16-0236.
- 27 S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. Version 2.3 (Februar 2018)
- 28 Perioperative Safety in the Longitudinal Assessment of Bariatric Surgery. N Engl J Med 2009; 361: 445-454 DOI: 10.1056/nejmoa0901836.
- 29 Birkmeyer NJO, Dimick JB, Share D. et al. Hospital complication rates with bariatric surgery in Michigan. JAMA – J Am Med Assoc 2010; 304: 435-442 DOI: 10.1001/jama.2010.1034.
- 30 Aberle J, Reining F, Dannheim V. et al. Metformin after bariatric surgery – An acid problem. Exp Clin Endocrinol Diabetes 2012; 120: 152-153 DOI: 10.1055/s-0031-1285911.